83 results about "Tgf beta1" patented technology

The present invention features non-human transgenic animal models for Alzheimer's disease (AD) and CAA, wherein the transgenic animal is characterized by 1) overexpression of bioactive transforming growth factor-beta1 (TGF-beta1) or 2) both overexpression of bioactive TGF-beta1 and expression of a human amyloid beta precursor protein (APP) gene product. The transgenic animals may be either homozygous or heterozygous for these alterations. Bigenic animals are further characterized by development of AD-associated and / or CAA-associated pathology within about two to three months of age.

This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and / or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and / or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and / or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.

The invention discloses a bionic oriented cartilage scaffold released by a two-factor program and a preparation method of the bionic oriented cartilage scaffold. The bionic oriented cartilage scaffoldis formed by compounding an upper layer of materials and a lower layer of materials, wherein a composite material of an upper surface layer is prepared from collagen, chitosan, hyaluronic acid and KGN-loaded PLAG microspheres; the composite material of a lower transition layer is prepared from collagen, chitosan, silk fibroin and TGF-beta1-loaded polylysine-heparin sodium (PLL-HS) nanoparticles.The bionic orientated cartilage scaffold prepared in the invention integrates high biocompatibility and biodegradability of collagen, antibacterial property and biodegradability of chitosan, high mechanical properties of silk fibroin and lubrication and anti-inflammation effects of hyaluronic acid, has good proliferation and differentiation promoting effects on BMSCs, can relieve and treat KOA symptoms while repairing early and middle KOA cartilage defects, and is a relatively ideal medical material for repairing osteoarthritis cartilage defects.

The invention discloses pulse ultrasound treatment equipment for male erectile dysfunction.The pulse ultrasound treatment equipment comprises a master control device, a micro-control system and a treatment probe.The treatment probe comprises an ultrasound generator.The master control device sends control signals to the micro-control system, the micro-control system converts the control signals into control instructions and sends the control instructions to the ultrasound generator, and the ultrasound generator generates corresponding ultrasound according to the control instructions.The pulse ultrasound treatment equipment can generate the ultrasound for therapeutic use, treatment is conducted in vitro in a non-intrusive mode, pain brought to a patient by an operation is avoided, and harm of medicine to the human body of dependence of the human body on the medicine are avoided.The low-intensity pulse ultrasound can promote neovascularization, proliferation of cavernous body smooth muscle cells and eNOS and nNOS expression, improve blood flow of the penis, lower a TGF-beta1 / Smad / CTGF signal channel and relieve fibrosis of the penis, the pathological change of the erection organ is improved accordingly, and finally the erection function of the penis is improved.

The invention relates to a therapeutic agent, composition and method for promoting restoration of hematopoiesis function, in particular to a hematopoiesis promoting therapeutic agent, composition and method for resisting toxic and side effect of radiotherapy and chemotherapy. The optical execution mode of the invention comprises a pharmaceutical composition contained IL-12 or pharmaceutical composition comprising at least two of the following protein factor: CSF-1,EGF,IGF-1,TNF-alpha,VEGF,MIP-1,IL-1,IL-6,FGF-1,FGF-2,FGF-7,PDGF,TGF-beta1,TGF-beta2,TGF-alpha,ANG-1,MCP-1,PF-4 or IL-8 The pharmaceutical composition can be administered before, in and after the basic therapy process like radiotherapy and / or chemotherapy.

The invention relates to an interference sequence-modified TGF-beta1 silent leukemia cell exosome and a preparation method and application thereof. Through expression of TGF-beta1 of a lentivirus vector silent exosome source cell with shRNA, the leukemia cell exogenic exosome, namely LEXTGF-beta1si of which the TGF-beta1 content is regulated down is produced and purified. The transformed leukemia cell exogenic exosome-sensitized dendritic cell is prepared into a DCLEX-TGF-beta1si vaccine. An in vitro and animal model experiment shows that the transformed vaccine is capable of generating more powerful specific anti-leukemia immunoreaction.

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and / or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.

The invention belongs to the technical field of medicine, and provides a PLGA (poly(lactic-co-glycolic acid)) porous composite microsphere preparation embedded with BMP-2 and TGF-beta1 containing microspheres therein, which not only can bring about benefits for the adhesion and the growth of seed cells by virtue of a 3D porous structure but also can undergo controlled- and sustained-release and can be applied to injection. The invention also provides a preparation method of the porous composite microsphere preparation as well as application of the porous composite microsphere preparation in preparing bone or cartilage tissue defect repairing materials. The porous composite microsphere disclosed by the invention, which can serve as a good carrier for cell adhesion and proliferation and can be directly injected to a target part, can offer a possibility of non-surgical repair to bone and cartilage tissue injuries; and the porous composite microsphere preparation is extensive in clinical application and market prospect.

The invention discloses a preparation method of a cell preparation for promoting the regeneration and the repair of traumas. The preparation method comprises the steps of shearing and digesting heel tendon tissues, carrying out centrifuging to remove supernate, adding an obtained tendon stem cell population into a culture solution, carrying out resuspension and filtering, inoculating the culture solution into a culture plate for culturing, mixing the culture solution with platelet rich plasma, and adding normal saline, so as to prepare a tendon stem cell population. Tendon stem cells are separated and cultured, tendon stem cells cultured in vitro are mixed with the platelet rich plasma to prepare the cell preparation, the platelet rich plasma contains a large number of growth factors such as PDGF, EGF, TGF-beta1 and IGF which have great promotion effects to the repair of tendons, the platelet rich plasma is capable of promoting the propagation of tendon cells and the expression of collagens I and III in vivo, and the tendon cells and the collagens I and III are key components of the tendons, so that an experimental result has a certain guiding effect to the repair of tendon injury of a human body.

The invention discloses a coaxial electrostatic spinning fibrous scaffold, belonging to the field of biological tissue engineering. The scaffold comprises an aliphatic polyester shell coupled with bone marrow derived mesenchymal stem cell (BMSC) affinity peptides and a polyvinylpyrrolidone core loading a recombinant human transforming growth factor (TGF)-beta1, not only is safe and non-toxic and has excellent biocompatibility but also can collect more BMSCs and promote chondrogenic differentiation of BMSCs, and then more cartilage tissues are obtained, so that cartilages are effectively and quickly repaired. The invention also discloses a preparation method of the coaxial electrostatic spinning fibrous scaffold. The preparation method comprises the steps of carrying out coaxial electrostatic spinning by using an aliphatic polyester shell solution and a polyvinylpyrrolidone core solution containing the recombinant human TGF-beta1 in the windless environment to prepare a fibrous scaffold; coupling the BMSC affinity peptides on the surface of the fibrous scaffold, thus obtaining a nanoscale coaxial electrostatic spinning fibrous scaffold. The method is simple, is easy to control and has relatively strong practicability.

The invention relates to a TGF-ss1 inhibitor peptide which is selected from among: peptide p144 having a sequence that corresponds to SEQ ID NO: 1, peptide p17 having a sequence that corresponds to SEQ ID NO: 2, a peptide that has at least 90 % homology with said peptides, or fragments of same. The invention relates to the use of said peptide in the preparation of an immune response modulating agent.

The invention discloses an effective method for differentiation induction from hPSCs to MSCs. The effective method comprises the following steps: 1) after transferring a hPSCs cell strain which is notdifferentiated on a culture plate coated with an extracellular matrix and culturing, culturing by using a differentiation culture medium which contains BMP-SMAD1 / 5 / 8 signal channel activator, a TGF-beta 1 / Activin / Nodal-SMAD2 / 3 signal channel activator, a Wnt activator and a PI3K inhibitor; 2) removing an old culture medium, and continuing to culture by using a differentiation culture medium whichcontains a TGF-beta1 / Activin / Nodal-SMAD2 / 3 signal channel inhibitor; 3) dissociating and transferring cells to a new culture plate, and continuing to culture by using a differentiation culture mediumwhich contains a TGF-beta1 / Activin / Nodal-SMAD2 / 3 signal channel inhibitor; and 3) dissociating and transferring cells to a wall-attached culture plate and continuing to culture so as to obtain MSCs.The complete scheme and method for differentiating into MSCs from hPSC in an oriented manner through a middle-section primitive streak stage or a side mesoderm stage is established in vitro. Comparedwith a conventional method, the effective method is simple in technical step, simple and easy to operate and high in reproducibility, and MSCs with mature phenotype and high quality can be obtained within 12 days only.

The invention discloses use of a transforming growth factor (TGF)-beta1 inhibitor in lung cancer treatment. The TGF-beta1 inhibitor inhibits a TGF-beta1 channel to increase the radiosensitivity of lung cancer cells. Through the manner, according to the use of the TGF-beta1 inhibitor in lung cancer treatment, the sensitivity enhancement effect of the TGF-beta1 inhibitor on the lung cancer cells is caused by inhibition on non-homologous end joining repair of deoxyribonucleic acid (DNA) double-strand break, change of cycle distribution of the lung cancer cells after irradiation, and obvious reduction of tumor growth by the TGF-beta1 inhibitor combined with X-ray treatment of 5Gy. The DNA repair capacity can be reduced by inhibition on the TGF-beta1 channel of tumor cells before irradiation, the cell cycle distribution is changed, the cell cloning ability is reduced, the tumor growth is delayed, and effective auxiliary means are provided by inhibiting the TGF-beta1 channel as radiotherapy of a patient with a lung cancer.

The invention discloses a medical new application of two halophenol compounds 4,5,2'-trihydroxy-2,5'-dibromobenzophenone and 4,5,2'-tri(4-morpholine methanoyl)-2,5'-dibromobenzophenone, in particular an application in preparation of medicines of resisting type II diabetic nephropathy. Meanwhile, the invention also discloses a medicine of resisting type II diabetic nephropathy employing the two halophenol compounds as active ingredients. By the two compounds, the renal function of the type II diabetic nephropathy can be effectively improved; the main treatment indexes, namely uric acid, urine protein, microalbuminuria, transforming growth factor TGF-beta1, blood sugar, low-density lipoprotein and the like are superior to those of an existing clinic first-line medicine captopril; and the important application prospect in treatment of the diabetic nephropathy is displayed.

The invention discloses a synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof, inhibits auxo-action of the cell factor TGF-B1-BB during the development process of liver fibrosis so as to inhibit the development of liver fibrosis to a some extent by constructing two epitope peptides of AY25 and LS30, coupling carrier proteins to synthesize an TGF-beta1 peptide vaccine, immunizing an ICR mice by intraperitoneal injection to induce the same to generate an anti-TGF-beta1 antibody, and neutralizing the cell factor TGF-B1-BB over expressed during CCL4 induced hepatic fibrosis process.

The invention relates to application of demethylwedelolactone-7-sulfate in preparation of an anti-pulmonary fibrosis drug. The compound demethylwedelolactone-7-sulfate is obtained from traditional Chinese medicine herba ecliptae for the first time and the structure of demethylwedelolactone-7-sulfate is determined through NMR (Nuclear Magnetic Resonance) and other wave spectrum data, the in-vivo and in-vitro pharmacological experiments prove that the demethylwedelolactone-7-sulfate can obviously inhibit the proliferation of TGF-beta1 induced human embryo lung fibroblasts and the HYP (hydroxyproline) content, the inflammation and fibrosis degree of lung tissue in bleomycin induced mice pulmonary fibrosis model can be reduced after the anti-pulmonary fibrosis drug is orally taken at a dosage of the 5-30mg / kg, the content of MDA (methylene dioxyamphetamine) reflecting the lung injury degree in lung tissues is influenced, the content of HYP reflecting the collagen deposition of lung tissue can be reduced, the content of cell factor TGF-beta1 causing pulmonary fibrosis can be reduced, and the like, so that the pharmacological action for improving the pulmonary fibrosis degree can be achieved. The demethylwedelolactone-7-sulfate has new applications as a drug for treating or improving pulmonary fibrosis disease.

The invention relates to application of STAT1 serving as ovarian cancer treatment target point. Experiments prove that the STAT1 directly combines with a TGF-beta receptor (ALK1, ALK5 and TbetaRII), proliferation, migration and invasion of ovarian cancer cells can be promoted after STAT1overexpression, and proliferation, migration and invasion of the ovarian cancer cells can be inhibited after STAT1 knocking-down. Therefore, STAT1 reduction processing is conducted on patients with high ovarian cancer STAT1 expressions, a potential treatment effect exists. An STAT1 signal path mutually acts with a TGF-beta1 signal path to influence the proliferation, migration and invasion capability of ovarian cancers. The STAT1 is a potential novel ovarian cancer treatment target point and has a great clinical application value.

The present invention relates to medical tissue engineering, and is process of preparing tissue engineering cartilage with inner support for use as permanent prosthesis clinically. The process includes the following steps: making inner support with nondegradable stable medical porous high-density polyethylene MEDPOR, coating the inner support with nonwoven net of degradable polyglycolic acid (PGA) with high biocompatibility to form compound MEDPOR-PGA rack, dropping prepared autologous marrow matrix stem cell suspension to the nonwoven PGA net, in vitro culturing to the inducing solution with DMEM cartilage connecting TGF-beta1,IGF-I and insulin for certain time, and implanting to under skin for 4-6 weeks to constitute the tissue engineering cartilage. The present invention makes it possible to prepare clinically essential permanent implant.

The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.

The invention relates to ganoderma cochlear phenols A and B, pharmaceutical compositions of ganoderma cochlear phenols A and B and applications of ganoderma cochlear phenols A and B and the pharmaceutical compositions thereof in preparation of medicines and food. Two racemates are separated from ganoderma cochlear and identified, and then the two racemates are split into two pairs of optical enantiomers which are named as levorotatory or dextrorotatory ganoderma cochlear phenols A and B respectively. Researches show that both the racemates and the enantiomers are capable of significantly inhibiting TGF-beta1-induced renal tubular epithelial cell from generating fibronectin, I type collagen and alpha-smooth muscle actin (alpha-SMA), and researches further find that both the racemates and the enantiomers are capable of significantly inhibiting the TGF-beta1-induced renal tubular epithelial cell Smad3 from phosphorylation, which means that the compounds have application prospects in the field of preparation of medicines for resisting renal fibrosis and chronic nephrosis.

The invention belongs to biotechnology field and particularly relates to high throughput screening of an effective anti-hepatic fibrosis compound by means of picric acid-sirius red staining method on a collagenous fiber. The cell is hepatic stellate cell line CFSC-8B, transforming growth factor TGF-beta1 with the dose of 10ng / mL can obviously induce the CFSC-8B cell to secrete collagen when acting for 48 hours, and the secretion of the CFSC-8B cell collagen induced by the TGF-beta 1 can be effectively detected by means of picric acid-sirius red staining method. The picric acid-sirius red staining method on the collagenous fiber is applied to screening the compounds with anti-hepatic fibrosis activities in different polarity extracts of antrodia camphorata, ganoderma lucidum, cephalosporium sinensis, cordyceps mortierella, armillaria and hericium erinaceus powder. Tests prove that n-hexane and chloroform extract of the antrodia camphorata, ethyl acetate extract from the cordyceps mortierella, and n-hexane, chloroform extract and ethyl acetate extract from the armillaria can effectively inhibit the secretion of the CFSC-8B cell collagen induced by the TGF-beta 1, the above extracts have dose dependent relationship, are significant in difference, and have an anti-hepatic fibrosis function, and other extracts do not have significant inhibition effect.

The invention provides application of costunolide in preparation of anti-hepatic fibrosis drugs and belongs to the technical field of medicines. The anti-hepatic fibrosis drugs are prepared through the costunolide, the usage of the costunolide is increased, and meanwhile the kind of the anti-hepatic fibrosis drugs is enriched. According to the record of the embodiment, the costunolide can restrainexpression of hepatic fibrosis main markers in TGF-beta1 induced LX-2 cells on mRNA and protein levels and can restrain the level of BDL induced hepatic fibrosis rat serum ALT / AST / ALP and expressionof hepatic tissue fibrosis markers on the mRNA and protein levels, and accordingly BDL induced rat hepatic fibrosis is restrained; and meanwhile, through the costunolide, the BDL induced rat hepatic pathologic structure can be further improved, and the collagen deposition situation in the BDL rat hepatic tissue is obviously relieved.

The invention relates to novel application of astragaloside, in particular to application of astragaloside in preventing and treating type 2 diabetic nephropathy, and provides a study on the protective effect and acting mechanism of astragaloside for type 2 diabetic nephropathy. The results indicate that the astragaloside is capable of reducing urinary albumin excretion rate in type 2 diabetic db / db mouse, improving glomerulus and renal tubule pathological injury, and reducing excretion of urine NAG, NGAL and TGF-Beta1. The astragaloside is also capable of inhibiting activation of Akt / mTOR, NFkB and Erk1 / 2 signal channels, with no significant hepatotoxicity present. In total, the astragaloside can protect type 2 diabetic nephropathy, and its acting mechanism is associated with the inhibition of Akt and its related signal channels.

The invention discloses application of microvesicles from bone marrow mesenchymal stem cells (MSCs) in preparing a drug for treating a kidney injury. According to the application, a recovery effect of the MVs (microvesicles) in a kidney fibration process is verified by in vivo experiments and in vitro experiments. Fibration of renal tubular epithelial cells is caused by TGF-beta1 in the in vitro experiments, the research indicates that the extends of a cell fibration lesion and a cell injury in an MV group are obviously reduced, a unilateral ureteral occlusion animal model is built, the research indicates that in an UUO (unilateral ureteral occlusion) mouse model, average levels of SCr (serum creatinine ), blood UA ( uric acid), urinary protein of an UUO mouse injected with the MVs fall remarkably, the further pathological observation indicates that the extent of the kidney tissue injury of the mouse is improved obviously, the extends of renal mesenchymal fibration, lymphocyte infiltration and renal tubular swelling and necrosis are reduced obviously, and the kidney histopathology grade falls remarkably. That the MSC-MVs have a kidney injury recovery effect on the mouse with the unilateral ureteral occlusion is proved.

The invention discloses a method for genetic modification of intestinal protobacteria based on microencapsulation treatment. The method mainly includes utilizing the method of synthetic biology to genetically transform the selected intestinal primary escherichia coli and then perform microencapsulation treatment. The biosafety synthetic biology technology is combined with the non-invasive optogenetic technique for the treatment of intestinal diseases, and the method has many advantages compared with the traditional methods for treating the intestinal diseases. The intestinal primary escherichia coli are subjected to genetic modification, and the intestinal colonization compliance of the microencapsulated protobacteria is improved in the later stage. A single functional bioactive molecule,that is, a transforming growth factor (TGF-beta1) secreted by the primary escherichia coli is taken as an example to study the application in treatment of inflammatory bowel disease (IBD). The methodprovides a new idea for studying the interaction between enteric microorganisms and the body.

The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2′-fluoro, 2′-O-methoxy and / or 2′-O-methyl modified nucleotides. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in a method for the prevention and / or treatment of glaucoma, posterior capsular opacification, dry eye, Marfan or Loeys-Dietz syndrome, riboblastoma, choroidcarcinoma, macular degeneration, such as age-related macular degeneration, diabetic macular endma, or cataract.

The invention provides applications of a TGF-beta1 receptor blocker in preparation of medicines treating the Hydatid disease. Concretely, through immune escape of TGF-beta1 receptor blockers for inhibition of infection of intermediate hosts by echinococcosis granulosis cysts, increase of the number of CD<4+>T cells, decrease of the number of CD<8+> T cells, raising of the CD<4+> / CD<8+>T cell ratio, decrease of the number of CD<4+>CD<25+> T cells, increase of expression of active receptors NKG2D of NK cells and raising of the cracking rate of target cells Yac-1 by NK cells in host cells are caused. Researches show that NK cell viability is in positive correlation with active receptor NKG2D number. Results show that the provided method can enhance inhibition of hosts to echinococcosis granulosis cyst infection effectively. The method can be used for treating the Hydatid disease effectively, and has good clinic application prospects.

The invention discloses a stem cell bioactive composition and a preparation method and application thereof. The stem cell bioactive composition comprises 1.69 to 22.24 pg / mL of EGF (epidermal growth factor), 2443.17 to 4459.43 pg / mL of bFGF (basic fibroblast growth factor), 1.44 to 134.36 pg / mL of beta-NGF (Beta-nerve growth factor), 1.55 to 355.14 pg / mL of VEGF (vascular endothelial growth factor), 11.87 to 159.70 pg / mL of PDGF-DD (platelet-derived growth factor), 135.79 to 688.13 pg / mL of KGF (keratinocyte growth factor), and 1176.99 to 3825.79 pg / mL of TGF-Beta1 (transforming growth factor beta-1); the stem cell bioactive composition has high purity, high yield and high bioactivity.